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This review article reports on the new field of stem cell therapy and tissue engineering
and its potential on the management of congenital heart disease. To date, stem cell
therapy has mainly focused on treatment of ischemic heart disease and heart failure,
with initial indication of safety and mild-to-moderate efficacy. Preclinical studies and initial
clinical trials suggest that the approach could be uniquely suited for the correction of
congenital defects of the heart. The basic concept is to create living material made by
cellularized grafts that, once implanted into the heart, grows and remodels in parallel
with the recipient organ. This would make a substantial improvement in current clinical
management, which often requires repeated surgical corrections for failure of implanted
grafts. Different types of stem cells have been considered and the identification of specific
cardiac stem cells within the heterogeneous population of mesenchymal and stromal
cells offers opportunities for de novo cardiomyogenesis. In addition, endothelial cells and
vascular progenitors, including cells with pericyte characteristics, may be necessary to
generate efficiently perfused grafts. The implementation of current surgical grafts by stem
cell engineering could address the unmet clinical needs of patients with congenital heart
defects.
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Introduction
Congenital heart disease (CHD) is defined as an abnormality in heart structure that occurs before
birth, while the fetus is developing (Sun et al., 2015). It represents the most common congenital
anomaly in newborn babies, with a reported prevalence ranging from 6 to 13 per 1000 live births.
In the UK alone there are∼4600 babies born with CHD each year (Tennant et al., 2010; Khoshnood
et al., 2012). Despite considerable progresses in surgical techniques and medical management
of newborns with CHD, there are still considerable mortality and morbidity associated with
Abbreviations: 3D, 3-dimensional; BMCs, bonemarrow-derived cells; BMMNCs bonemarrowmononuclear cells; BP, bovine
pericardium; CHD, congenital heart disease/defect; CPs, cardiac pericytes; CSCs, cardiac stem cells; ECM, extracellular
matrix; ECs, endothelial cells; EPCs, endothelial progenitor cells; HF, heart failure; HLHS, hypoplastic left heart syndrome;
HPs, heart pericytes; iPS, induced pluripotent stem cells; IVC, inferior vena cava; LV, left ventricle; LVOT, left ventricle outflow
tract; MI, myocardial infarction; MMPs, matrix metalloproteinases; MSCs, mesenchymal stem cells; PCL, poly-Caprolactone;
PGA, poly-Glicolyc Acid; PLLA, poly-L-Lactic Acid; RA, right atrium; RV, right ventricle; RVEF, right ventricle ejection
fraction; RVOT, right ventricle outflow tract; TE, tissue engineering; ToF, Tetralogy of Fallot; UCBMNCs, umbilical cord
blood mononuclear cells; VEGF(R), Vascular Endothelial Growth Factor (Receptor); VICs, valve interstitial cells; VSMCs,
Vascular Smooth Muscle Cells.
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severe forms of CHD, which comprise the first cause of mortality
by congenital abnormalities (Khoshnood et al., 2012).
In the last decade, clinical needs of CHD have extended to the
adulthood. Recent estimations indicate that 80% of neonates and
infants with CHD can expect to reach adulthood (Woodward,
2011; Khoshnood et al., 2012). According to the Department
of Health, in 2006 there were around 135,000 adults living in
England with CHD (http://webarchive.nationalarchives.gov.uk/).
The 32nd Bethesda Conference report estimated that there were
approximately 2800 adults with CHD per 1 million population
and that more than half of them have a moderate or high
complexity defect (Baumgartner et al., 2010). These patients often
develop heart dysfunction and failure as well as neurological,
respiratory and coagulation problems (British Heart Foundation
Statistics Database: www.heartstats.org). The economic and social
burden of CHD is high and rapidly increasing. In 2004, the
U.S. hospital costs for CHD totaled $1.4 billion (Henaine et al.,
2012).
Typical congenital abnormalities comprise valves defects,
atrial and ventricular septa defects, stenosis and alterations of
the aorta and pulmonary veins and arteries and heart muscle
abnormalities. The defects can range in severity from relatively
simple problems, such as holes between chambers of the heart
that can be surgically closed, to very severe malformations, such
as the complete absence of one or more chambers or valves,
which cause deficits in blood oxygenation and circulation, heart
failure (HF), and eventually premature death (Woodward, 2011;
Sun et al., 2015). Common single CHD are represented by
holes (intra-cardiac shunts) inside the internal wall of the heart
(Figure 1, left): in septal defects, oxygenated blood returning
from the pulmonary veins flows from the left to the right
chambers of the heart, where it mixes with deoxygenated blood
returning from the body, finally causing an overloading of the
right ventricle (RV) (Geva et al., 2014; Sun et al., 2015). With
time this overload induces remodeling of pulmonary vasculature
and hypertension with consequent inversion of the shunt and
cyanosis (Woodward, 2011; Sun et al., 2015).Whenmixed lesions
are present at the same time the pathology increases in severity
and results in complex CHD (Figure 1, right). The most common
one is Tetralogy of Fallot (ToF), which features four cardiac
abnormalities: narrowing of the pulmonary outflow tract, a hole
connecting the ventricular chambers, RV hypertrophy, and the
aorta that lies over the hole between ventricular chambers. In
ToF patients, an outflow obstruction prevents the blood flowing
from the RV into the pulmonary artery, causing deoxygenated
blood to pass through the ventricular hole into the left ventricle
(LV) and then into the aorta (Woodward, 2011; Wald et al.,
2014). Another very serious condition is the hypoplastic left
heart syndrome (HLHS) (or univentricular heart syndrome),
characterized by hypoplasia of the LV, the aorta and related
valvular components, with systemic flow becoming dependent
on a patent ductus arteriosus. In this condition, blood returning
to the heart from both the systemic circulation and the lungs
mixes before being pumped by the RV to both the systemic
and pulmonary circulation, causing severe cyanosis, increased
pressure workload and ultimately failure of the RV (Barron et al.,
2009).
This review focuses on stem cell therapy and tissue
engineering as a new option to implement current surgical
methods for definitive correction of CHD. The approach was
initially conceived with the objective to repair and/or replace
damaged tissues and organs. However, stem cells from young
individuals possess superior naivety and plasticity than adult
stem cells and could be better suited for regenerative purposes.
The use of scaffolds engineered with stem cells may offer
unprecedented therapeutic opportunities for addressing unmet
clinical needs of patients with complex cardiac defects.
Elective Surgical Correction
The ideal therapeutic option for CHD patients is one-step
corrective surgery, during which the heart surgeon closes holes
in the heart with stitches or a patch, repairs or replaces valves,
widens arteries, and restores the proper location of major blood
vessels (Sun et al., 2015). In patients with ToF, the definitive
goals are relief of all obstruction to blood flow from the
RV to the pulmonary artery and closure of the ventricular
septum defect. Reconstruction of RV outflow tract (RVOT)
obstruction may involve resection of obstructing muscle bundles,
creation of an RVOTpatch, pulmonary valvotomy or valvectomy,
and pulmonary arterioplasty (Henaine et al., 2012). However,
complex CHD usually require more than one open-heart surgery
to correct the structural alterations (Woodward, 2011). On the
one hand, palliative procedures may be indicated to relieve
symptoms of acute HF, allowing definitive correction to be
performed when the baby has gained weight and hemodynamics
are stabilized (Yuan and Jing, 2009). For instance, babies with
HLHS require a surgical palliation within few days from birth
as the risk of death is 95% within few weeks from birth
without any treatment (Barron et al., 2009; Frescura and Thiene,
2014; Ishigami et al., 2015). On the other hand, multiple re-
interventions become often necessary because of deterioration
of the implanted grafts (Said and Burkhart, 2014). Patients at
the highest risk of death and not suitable for reparative or
palliative surgery are candidate to heart transplantation, this
extreme option being limited by shortage of donors (Razzouk and
Bailey, 2014; Hsu and Lamour, 2015; Ishigami et al., 2015; Sun
et al., 2015).
Limitations of Current Surgical Approach
The use of prosthetic materials in the form of conduits, patches
and new valves made by xenografts, homografts, or autografts is
routine in congenital cardiac surgery. Even though these grafts
may be life-saving, they are characterized by some limitations,
represented by a limited durability, and the risks of infection,
host immune response, and thrombotic complications. A crucial
problem still to be overcome in the pediatric population is
the lack of growth and remodeling potential of the grafts
currently used for CHD surgery (Mirensky and Breuer, 2008).
In the following paragraphs, we illustrate the advantages and
disadvantages of clinically available grafts. Additionally, these
aspects will be reconsidered in the perspective of creating
cellularized scaffolds in a subsequent section of this review.
Xenografts are biological grafts deriving from animals,
commonly porcine and bovine, largely used in surgery because
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FIGURE 1 | Cartoon illustrating the cardiac structural alterations in common single and complex CHD.
of the shortage of human substitutes. Xenogenic bovine
pericardium and porcine valves remain the first choice for heart
valve substitution (Yap et al., 2013). The porcine valve has
the advantage of adequate anatomic structure and unlimited
availability. The bovine pericardium contains a higher amount of
layered structural proteins than autologous human pericardium,
giving it elastic properties that allow conformity to complex
anatomical geometries, optimal for RVOT reconstruction (Pok
and Jacot, 2011; Strange et al., 2015). In order to avoid
the activation of the recipient’s immune response, xenografts
are decellularized, a process during which animal cells are
removed from the graft while the extracellular matrix is
preserved, to provide the remaining scaffold with the original
anatomical structure (e.g., valve) and the adequate support
for the recolonization by the patient’s cells after implantation.
Different methods have been used for this purpose, among
which there are enzymatic cell lysis (Trypsin), detergents and
chemicals cell removal (Sodium dodecyl sulfate, Sodium Azide,
and Sodium deoxycholate), freeze drying, and a combination of
chemical and enzymatic methods (Rieder et al., 2004; Schmidt
et al., 2007; Tudorache et al., 2007). An additional type of
xenograft manufacture includes cross-linking with chemicals
(such as glutaraldehyde), a process by which proteins are cross-
linked and collagen fibers stabilized, conferring the graft with
tensile strength, elasticity and resistance to degeneration; due
to their cytotoxicity, these chemicals eliminate also xenogenic
cells (Schmidt et al., 2007; Butcher et al., 2011). However,
improvements in pliability and tolerogenicity come at a price
(Figure 2). In fact, elimination of valve interstitial cells (VICs),
which normally ensure the regular turnover of the valve
extracellular matrix (ECM), makes prostheses more susceptible
to degeneration, both in vitro and after implantation in
a mechanical environment. The seeding of VICs onto the
decellularized scaffolds has been proposed to overcome this
problem; furthermore, the reseeding of the graft using cells able
to produce new ECM is crucial to prevent the degeneration
of the graft structure (Cushing et al., 2005). Noteworthy,
while decellularized grafts are metabolized and remodeled by
matrix-metalloproteinases (MMPs) after implantation in the
patient, cross-linked grafts do not allowMMPs degradation, thus
interfering with the remodeling process (Schmidt et al., 2007).
In fact, to preserve the mechanical properties of biological grafts,
the remodeling process should be balanced between the matrix
formation and degradation. Last, atherosclerotic processes
also participate in prosthetic valve remodeling, with initial
accumulation of oxidized low-density lipoproteins, followed by
monocyte recruitment, generation of a pro-inflammatory milieu,
collagen disruption and osteogenic differentiation of resident ECs
and precursor cells recruited from the circulation (Shetty et al.,
2009; Gossl et al., 2012).
Cryopreserved homografts—usually valves or vascular
conduits—are derived from humans, commonly cadavers. They
are the heart valve replacements closest to the natural valve,
being non-thrombogenic and having a low risk of infection.
Cryopreserved homografts have been used for many years in
CHD surgery, for pulmonary or aortic valve replacement, or
for RVOT reconstruction during the Ross operation (Gabbieri
et al., 2007; Neumann et al., 2013). Homografts are not
chemically cross-linked and exhibit good mechanical properties.
Disadvantages are their limited availability, more difficult
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FIGURE 2 | Cartoon illustrating the mechanisms of prosthetic valve
degeneration. Xenogenic or allogenic valves are decellularized to reduce
the risk of immune response and rejection. In addition, animal derived valves
can be cross-linked with glutaraldehyde. The three main mechanisms of
valve failure are structural deterioration, fibrosis and calcification, and
damage by rejection from the host immune system.
implantation techniques and failure associated with a specific
immune response, especially in young individuals. Although
homografts have been associated with a very good hemodynamic
performance, the cryopreservation and the thawing process can
produce the structural deterioration of the matrices, limiting the
durability of the graft (Neumann et al., 2013). In the younger
patients, the risk of structural valve deterioration ranges from 71
to 87% at 10 years (Ruel et al., 2005).
Decellularized homografts have been proposed as a good
alternative, showing lower explantation and degeneration rates
than conventional cryopreserved valve grafts (0–10% vs. 30%
after 5 years, respectively) (Cebotari et al., 2011; Ruzmetov et al.,
2012). Additionally, implantation of decellularized homografts
is reportedly associated with spontaneous recellularization (da
Costa et al., 2005; Dohmen et al., 2006b; Cebotari et al., 2011).
Autografts are created using the patient’s own tissues.
Pulmonary autografts are commonly used in children and young
adults with ToF or valves defects. During the Ross procedure, the
surgeon replaces the aortic valve with the autologous pulmonary
valve of the patient, and performs the reconstruction of the
RVOT using a prosthetic valve (Al-Halees et al., 2002). A study in
30 children demonstrated the growth of the pulmonary autograft
in parallel with somatic growth (Simon et al., 2001). However,
autografts are prone to dilatation with subsequent aortic valve
regurgitation (Dohmen et al., 2002). The freedom from RVOT
replacement for children is reported to be about 90% at 12
years (Pasquali et al., 2007). Independently of the material
used, prosthetic reconstruction of RVOT is often associated
with mechanical and electrical abnormalities arising from non-
contractile/non-conductive patch material (Tweddell et al., 2000;
Perri et al., 2012).
Autologous pericardium is easily harvested during cardiac
surgery, but is difficult to handle since it has a propensity to roll at
the edges rendering the procedure difficult and time-consuming
(Pok and Jacot, 2011).
Synthetic Gore-Tex andmechanical valves are durable but lack
of growth potential; moreover, mechanical valves require chronic
anticoagulation treatment to reduce the risk of thrombosis.
Careful monitoring of coagulation parameters is necessary to
avoid bleeding complications (Said and Burkhart, 2014).
Considering limitations and limited durability of available
prostheses, there is an urgent need of new therapeutic strategies
to optimize long-term outcomes in CHD patients. Recent
advances in regenerative medicine allow the manipulation of
a spectrum of stem/progenitor cells, including endothelial,
mesenchymal, and cardiac stem cells, to support the youngest
heart repair. In the following sections, we will report two
main approaches of regenerative medicine, namely stem cell
therapy (transplantation of dispersed stem cells) and tissue
engineering (use of grafts functionalized with single or multiple
stem cell types). Stem cell therapy has provided first proof-of-
concept, thus paving the way to tissue engineering to fabricate
cellularized valves endowed with anti-coagulative properties and
living cardiac tissue that grows physiologically in parallel with the
heart’s growth.
Stem Cell Therapy for CHD
Cell therapy holds promises for treatment of a range of disabling
diseases. This therapeutic strategy is based on the injection of
dispersed cells in the site of damage, aimed at stimulating the
regeneration of the damaged tissue and possibly the recovery
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of its function. In the heart, different ways of delivery can
be used, that are intracoronary, intramyocardial, intravenous,
and epicardial. The therapeutic effects can be determined by
a direct cellular effect, given by transdifferentiation of injected
cells in cardiovascular cells, or more likely by a cytokine-
paracrine effect, that means cells release soluble factors that
exert protective effects on neighboring cells, although not
participating in the formation of new functional tissue by trans-
differentiation (Krause et al., 2010). From recent studies a
new paracrine mechanism has emerged, based on the release
of intracellular material—mainly proteins and micro-RNA—by
particular vescicles called exosomes (Ibrahim et al., 2014).
In the cardiovascular medicine field, stem cell-based therapies
have been principally applied to the treatment of adult patients
with myocardial ischemia or HF (reviewed in Sanganalmath
and Bolli, 2013). The first two randomized phase I clinical
trials, SCIPIO and CADUCEUS, in which respectively c-Kit-
positive Cardiac Stem Cells and Cardiosphere-derived Cells
were administered to end-stage HF adult patients, showed
positive outcomes regarding safety and efficacy of cell therapy
(Bolli et al., 2011; Makkar et al., 2012). Only recently, the
approach has been proposed for correction of congenital cardiac
defects (Bernstein and Srivastava, 2012; Pincott and Burch,
2012).
Which Cell Type Should Be Used?
A comprehensive solution for complex cardiac defects like ToF
requires the generation of valves and grafts containing a spectrum
of regenerative cells. On the one hand, the use of multipotent
stem cells able to generate all the components of the cardiac
tissue, i.e., vascular cells, cardiomyocytes, and stromal cells,
represents an option. On the other hand, the combination of
different progenitor cells with restricted and predictable lineage
commitment might be preferred by regulatory agencies for safety
reasons. Hence, at this stage, research on different cell types
should be pursued.
Induced Pluripotent Stem Cells
Induced pluripotent stem cells (iPS) are pluripotent cell lines
obtained from the ex vivo reprogramming of fetal or adult
somatic cells, like fibroblasts. During the reprogramming
process, commonly four classical recognized pluripotency factors
(NANOG, OCT-4, c-MYC, and KFL-4) are introduced within the
cells from an ectopic source, usually carried by retroviral vectors.
Reprogrammed cells are characterized by a high plasticity, being
able to differentiate in cells of the three embryonal germ layers
and thus potentially having the capacity to differentiate in
most of the human body’s cells (Takahashi et al., 2007; Yu
et al., 2007). These last properties make iPS a good choice
for application in regenerative medicine. For employment in
CHD surgery, iPS derived from the patient’s cells could be
ideally differentiated in vitro in vascular and myocardial cells
before autologous transplantation (Lundy et al., 2013; Yoder,
2015). To date, the limitation to the clinical use of these
cells is given by the risk of tumorigenesis deriving from
the genomic integration of the viral vectors (Mayshar et al.,
2010).
Foetal and Umbilical Cord Cells
The time of diagnosis is key for the decision. Owing to advances
and diffusion of pre-natal cardiac imaging, it is now possible
to recognize cardiac defects in a large proportion of subjects.
For these cases, foetal cells and umbilical cord cells represent
valid therapeutic candidates and, in the future, in utero repair of
cardiac defects using these cells will become a routine practice.
Umbilical cord is collected at the time of birth; umbilical cord
blood mononuclear cells (UCBMNCs) can be isolated from
the blood, while mesenchymal stem cells are extracted from
the Wharton’s jelly. Cord stem cells are able to differentiate in
cardiomyocyte-like cells and endothelial cells (ECs) (Chen et al.,
2009; Wu et al., 2009). Last year, the Mayo Clinic announced
the first U.S. stem cell trial with autologous umbilical cord blood
cells to treat children with HLHS (http://www.mayo.edu). Foetal-
derived stem cells can be isolated from the amniotic fluid and
include both pluripotent stem cells and more committed cells
(Klemmt et al., 2011). Foetal cells could be stored, according to
the large experience accumulated with umbilical cord blood cells,
and used for multi-stage corrections.
Adult Cells
Despite the promising potential of iPS and foetal cells, so far
most preclinical and clinical studies have employed post-natal
cells for both safety reasons and easy accessibility to adult tissues.
Different cell types derived from post-natal tissues can be used.
Endothelial cells and progenitor cells
Initial focus of research has been the re-endothelialization of
cardiac valves to reduce thrombotic complications. Optimal
candidates for this purpose are ECs and endothelial progenitor
cells (EPCs). The first can be isolated from peripheral, easy
accessible veins, such as the saphenous or forearm veins, while
the second ones can be purified from the peripheral blood or
bone marrow. EPCs can circulate in peripheral blood and can
be incorporated in regions of active neovascularization, such
as the ischemic myocardium (Xin et al., 2008). Experimental
evidence suggests that EPCs participate not only in the process
of vasculogenesis substituting the lost ECs but also in the
endothelialization of grafts (Young et al., 2007). The significance
of EPCs in cardiovascular disease has been reviewed in Madonna
and De Caterina (2015).
Mesenchymal stem cells
Mesenchymal stem cells (MSCs) are a heterogeneous subset of
stromal stem cells that can be isolated from many adult tissues,
including the heart, skeletal muscle, bone marrow and adipose
tissue (Uccelli et al., 2008). MSCs stand out as an encouraging
option for cell therapy due to their accessible isolation, great
expansion potential, immunoregulatory activity and angiogenic
properties (Dimarino et al., 2013). Not less relevant, MSCs
possess a multipotential differentiation capacity, being able to
differentiate, in vitro, into cells of the mesodermal lineage
(Dominici et al., 2006), and possibly toward cells of endoderm
and ectoderm derivation (Uccelli et al., 2008). In vivo, although
being able to generate new cardiomyocytes and vascular cells,
MSCs stimulate vascular and cardiomyocyte regeneration acting
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prevalently by paracrinemechanisms (Gnecchi et al., 2006, 2012).
Also, they may positively influence cardiac metabolism and
contractility (Gnecchi et al., 2012). The immune compatibility of
the MSCs is a remarkable advantage for the translation of their
use in clinics (Castro-Manrreza and Montesinos, 2015).
Bone marrow-derived progenitor cells
Total bone marrow-derived cells (BMCs) and especially
subpopulations of bone marrow mononuclear cells (BMMNCs,
that means either MSCs, or hematopoietic stem cells (HSCs),
or monocytes) have been used in transplantation trials in
acute myocardial infarction (MI) patients (reviewed in Simari
et al., 2014). The advantage of using these cells is the easy
accessibility with low risks for the patients, and the possibility
to harvest high numbers of cells without requirement of long
time in vitro expansion. The mechanisms by which BMCs
can contribute to an improvement of cardiac function after
transplantation in the patient heart are still debated, but
two main mechanisms have been proposed: (1) paracrine
influence on surrounding cardiac cells (Uemura et al., 2006),
and (2) variable levels of transdifferentiation in ECs, pericytes,
VSMCs and cardiomyocytes (Hosoda et al., 2010; Yoon et al.,
2010). Noteworthy, the potential of transdifferentiation in
cardiomyocytes still represents an open challenge for stem cell
scientists; regarding the BM-MSCs subpopulation, there are
discrepancies between scientists who reported the cells ability
to generate new cardiomyocytes in vivo post-MI (Kawada
et al., 2004; Yoon et al., 2005) and those who showed, instead,
that BM-MSCs have very limited ability to generate functional
contractile cardiac cells (Rose et al., 2008; Beitnes et al., 2009;
Dixon et al., 2009; Tendera et al., 2009; Wohrle et al., 2010).
Conversely, this cardiogenic ability has been negated to HSCs
(Balsam et al., 2004; Murry et al., 2004).
Cardiac stem cells
Harvesting MSCs from accessible sources, like the subcutaneous
adipose tissue, represents an attractive option. However, MSCs
present in the stroma of different tissues are heterogeneous
and may be influenced by the specific environment where they
reside. The idea of using more specialized cell populations was
pursued with the use of MSCs obtained from the target organ:
the heart. Several investigations over the last 15 years have
demonstrated that new cardiovascular cells are generated starting
from primitive undifferentiated cells (cardiac stem cells—CSCs)
resident in the heart since from birth, with this phenomenon
playing a primary role after an acute injury as a myocardial
infarction (Torella et al., 2006; Bearzi et al., 2007; Hsieh et al.,
2007; Bergmann et al., 2009). Several CSC classes have been
identified in the adult human heart, based on the expression
of different markers (Torella et al., 2007; Beltrami et al.,
2011; Bernstein and Srivastava, 2012). The most extensively
characterized CSCs express the Stem Cell Factor-receptor (SCF-
R, also named c-Kit), the Stem Cell Antigen-1-like (Sca-1) and
the Multidrug Resistance-1 (MDR-1, receptor which belongs to
the class of ABC transporters that mediate the Hoechst dye
eﬄux from the cell) (Muller et al., 2002; Quaini et al., 2002;
Messina et al., 2004; Bearzi et al., 2007). All the above cells do
not express transcription factors or membrane and cytoplasmic
proteins shared by mature cell types, and thus they are defined as
Lineage-negative (Lin-); moreover CSCs are characterized by the
capacity of self-renewal, clonogenicity, and multipotency, being
able of differentiation in all the mature cardiovascular cell types.
All the mentioned properties are essential for the formation
of new cardiac tissue, although this latter phenomenon is not
sufficient to restore a massive loss of tissue (Muller et al., 2002;
Quaini et al., 2002; Messina et al., 2004; Bearzi et al., 2007).
Combinatory cell therapy
The heart is made by different types of cells. Therefore, optimum
cell therapy for cardiac repair may require the association of
different cell populations with complementary activities leading
to balanced cardiomyogenesis/vasculogenesis. Apart from a
recent study reporting the benefit of associative treatment with
human MSCs and human c-Kit+ CSCs in an immunosuppressed
swine model of myocardial infarction (Williams et al., 2013),
combinatory cell therapy has received very little attention. We
recently reported the advantage of dual therapy with CSCs and
vascular pericytes for harmonized repair of the infarcted heart in
mice (Avolio et al., 2015a). Interestingly, the two cell populations
exert reciprocally enhancing paracrine activities, which lead
to increased proliferation of vascular cells and cardiomyocytes
and attraction of endogenous CSCs. These seminal examples of
combinatory cell therapy set the basis for fabrication of scaffolds
functionalized with multiple cell types.
Stem cells in the youngest heart
Despite minor attention has been focused on the pediatric
heart, a few studies displayed that CSCs are more abundant
in the neonatal period and rapidly decrease over time, making
myocardial samples from the youngest hearts an optimal source
of stem cells for use in reconstructive surgery (Peral et al., 2014).
In particular, the histological examination of RV biopsies from
CHD patients aged 2–93 days demonstrated that c-Kit-positive
CSCs are four-fold more abundant during the first post-natal
month (0.4 vs. 0.1% of total cardiac cells at birth and after 1
month, respectively), and a similar reduction was observed also
for NKX2.5-positive cells (Amir et al., 2008). Moreover, Mishra
et al., compared c-Kit-positive CSCs isolated from right atrial
(RA) specimens of CHD patients selected on the basis of 3
different groups of age: neonates (<30 days), infants (1 month to
2 years) and children (2–13 years), and showed that c-Kit-positive
CSCs are two- and three-fold higher in neonates than in infants
and children respectively, along with a superior differentiation
potential (Mishra et al., 2011). Similarly, a comparison of human
hearts aged between 9 days to 77 years showed that the number of
CSCs isolated permg of cardiac tissue was more than three-fold
higher in the youngest hearts (Tateishi et al., 2007). In addition to
these considerations, a study performed in children aged 19 days
to 16 years affected by univentricular heart and chronic pressure
overload, showed that the number of c-Kit-positive cells in RV
of patients is three-fold higher than in cardiac biopsies post-
transplantation, suggesting that the pressure overloadmay lead to
an increase in resident CSCs (Rupp et al., 2012a). This latter may
represent an adaptive response in CHD children in the attempt
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to counteract the alterations in cardiac function, although not
sufficient to overcome the challenges of severe CHD.
But stem cells resident in neonatal hearts are not only more
abundant than the adult counterparts. A study performed by
Simpson et al., showed that c-Kit/CD90-positive CSCs generated
from neonatal RA samples are also endowed with a superior
regenerative ability than CSCs derived from adult samples, when
transplanted in a rat model of acute myocardial infarction
(Simpson et al., 2012). Authors showed that neonatal CSCs
are characterized by higher levels of c-Kit, flk-1 and Islet-1-
positive cells in comparison with the adult ones; the younger
cells possessed also an increased cardiomyogenic potential both
in vitro and in vivo, preventing the formation of the fibrotic scar
and improving cardiac functional recovery when transplanted in
the animal hearts. Authors supposed that a possible explanation
for this augmented regenerative ability of neonatal CSCs might
derive from the higher secretion of pro-angiogenic factors, like
Vascular Endothelial Growth Factor (VEGF) and Angiogenin,
which play a crucial role during the formation of new blood
vessels (Simpson et al., 2012).
Besides the abovementioned CSC classes, other cell types have
been isolated from the youngest human heart, and may represent
a valid option in cell therapy for correction of CHD. Very
recently, a population of heart pericytes (HPs) has been identified
by the group of B. Péault inmyocardial samples from both fetuses
at 17–23 weeks of development and post-mortem adults. HPs,
recognized as CD34/45-negative and NG2/PDGFR-β/CD146-
positive cells, possess a multilineage mesodermal differentiation
potential, including limited cardiomyogenic properties both
in vitro and in vivo in a mouse model of MI, and marked pro-
angiogenic ability in vitro (Chen et al., 2015). Despite this, the
potential of these cells has not been evaluated immediately after
birth yet. Instead, our group has recently been involved in the
isolation and characterization of a population of cardiac pericytes
(CPs) from myocardial leftovers of neonates and children
operated for correction of CHD (Avolio et al., 2015b). We
originally select CPs as CD34-positive CD31-negative cells, and
after expansion CPs express pericyte (NG2/PDGFR-β) along with
stemness markers (NANOG, OCT-4, SOX-2), are clonogenic and
endowed with ability to differentiate into VSMCs, but not into
ECs or cardiomyocytes. We demonstrated that CPs are able to
attract endothelial and cardiac stem cells in an in vitromigration
assay, and support the network forming ability of ECs in an
in vitro angiogenic assay (Avolio et al., 2015b). Last, in the
human fetal aorta a population of CD133/CD34/VEGFR-positive
vascular progenitor cells has been identified and characterized for
its unique vasculogenic andmyogenic potential in amousemodel
of limb muscle ischemia (Invernici et al., 2007).
Preclinical Trials
Since the complex nature of congenital heart defects makes
these latter difficult to reproduce in animals, there are no
many animal models of CHD, and this represents a significant
limit in the translation of new therapies to clinic (Peral
et al., 2014; Tarui et al., 2014). Nevertheless, in the last years
some efforts and progresses have been done, in particular to
reproduce an increased pressure or volume overload of the
RV that is a common feature in patients with a HLHS or
ToF. Although it is difficult to make an animal model that
mimics univentricular hearts, a pressure-overload right-heart
model using pulmonary artery banding has been developed
in rats (Hoashi et al., 2009) and sheep (Davies et al., 2010),
which is useful to evaluate the safety and efficacy of cell
transplantation in presence of single ventricular lesions. In these
studies, skeletal myoblasts (Hoashi et al., 2009) and cord blood
stem cells (Davies et al., 2010) were injected in the animal
hearts, determining an improvement of RV function. Also, a
first murine model of RV volume overload has been obtained
by Reddy et al., by entrapping the pulmonary valve leaflets with
sutures (Reddy et al., 2013). In addition, a recent study performed
in a piglet ToF model showed the safety and feasibility of
intramyocardial administration of human MesP1 (mesodermal
posterior 1)-positive /SSEA-1(stage specific embryonic antigen-
1)-positive embryonic stem cell-derived cardiac progenitors 4
months after a surgical procedure mimicking the repair of ToF.
This latter consisted of an enlargement of the RVOT by a
polytetrafluoroethylene patch, the excision of one pulmonary
valve leaflet and a pulmonary artery banding. At 3months follow-
up, animals receiving cell therapy showed some improvements
in RV remodeling (reduction of peri-myocyte fibrosis) but
unfortunately no significant improvement in RV function
compared to control animals (Lambert et al., 2015). Finally,
the feasibility and long term safety of autologous UCBMNCs
transplanted intramyocardially into the RV of piglet hearts was
recently demonstrated (Cantero Peral et al., 2015).
Clinical Trials in Children with CHD
So far, major attention has been dedicated to the therapy of
pediatric dilated cardiomyopathy (Rupp et al., 2009; Bergmane
et al., 2013; Selem et al., 2013), while experience with stem cell
therapy in children with severe CHD or acquired heart failure
has been limited to single cases and small-size cohorts.
In 2010, Rupp et al., reported a case of cell therapy with
intracoronary injection of autologous BMCs in an 11-months-
old boy with HLHS; although this was only an isolated case,
the patient outcome was dramatically improved 3 months after
cell therapy, with RV ejection fraction (RVEF) increasing from
22 to 44% (Rupp et al., 2010). More recently, intraoperative
administration of autologous UCB-stem cells in a 4-months-old
baby undergoing a second palliation surgery gave positive results,
improving the RVEF from 30 to 50% at 3 months of follow-
up (Burkhart et al., 2015). Again, another study performed in
9 children with severe terminal HF (6 with HF secondary to
dilated cardiomyopathy and 3 with CHD) showed the feasibility
and safety of intracoronary infusion of autologous BMMNCs,
stabilizing patients conditions during the short (3 months) and
long term (up to 52 months) follow-up (Rupp et al., 2012b).
The first long term follow-up phase I controlled clinical trial
in pediatric patients with CHD, using autologous CSCs, has been
concluded only recently (Ishigami et al., 2015). In the TICAP trial
(Transcoronary infusion of Cardiac progenitor Cells in patients
with single ventricle physiology), autologous CSCs were isolated
from 7 children affected by HLHS, aged 5 months to 3 years, and
administered via intracoronary delivery 4–5 weeks after surgical
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palliation. Seven children were selected as control (received
palliation surgery without cell therapy). The administration
procedure was safe, without any serious adverse event. At 18
months of follow-up, the CSC-treated patients demonstrated
an improvement in RVEF from an average baseline value of
47 to 54%, whereas control patients showed little improvement
in RVEF, from 47 to 49% (Ishigami et al., 2015). This study
gave the first important demonstration of safety and feasibility
of autologous CSCs application in young CHD patients. The
same group is now carrying out a larger phase II study (Cardiac
progenitor Cell infusion to treat univentricular heart disease:
PERSEUS), which involves 34 patients randomly assigned to the
treatment or control group, to strengthen the positive results
collected during the first phase (Tarui et al., 2014).
Tissue Engineering for CHD correction
Tissue engineering is a promising bioengineering technology
that aims at the creation of unique substitutes using three-
dimensional synthetic or biologic scaffolds seeded with
autologous stem cells and differentiated cells, to allow individual
patients therapy with regeneration, remodeling and growth
potential (Cheema et al., 2012; Smit and Dohmen, 2015). On the
one hand, scaffolds serve as a site of cell attachment and new
tissue formation. On the other hand, their recolonization by cells
after implantation seemingly contributes to the creation of a
living tissue perfectly integrated in the recipient’s organ. Seeded
cells may contribute to the homing of resident cells by secretion
of chemoattractant factors.
Tissue engineering has been one of the most promising
strategies for the regeneration of impaired tissues. For instance,
a tissue engineering approach has been used successfully for
the repair of injuries to, or congenital absence of complex
organs such as the trachea, esophagus, or skeletal muscle
(Macchiarini et al., 2008; Badylak et al., 2012). The first
success, in 1994, was the reproduction of tracheal cartilage
using tissue engineering techniques (Vacanti et al., 1994). Later,
bioengineering techniques have been applied also to the heart.
Experience accumulated in adult patients suggests that dispersed
stem cells may die soon after implantation in the heart, their
therapeutic action being attributable to paracrine factors released
during the initial post-transplantation phase. Therefore, this
approach does not seem to be advantageous for the repair of
complex congenital defects, that frequently requires additional
tissue in various forms, such as patches, valves and conduits
(Dean et al., 2012; Kalfa and Bacha, 2013; Smit and Dohmen,
2015). Stem cells may work more efficiently if embedded in
extracellular matrices, prosthetic grafts and patches to create
biological structures that, once implanted in the defective heart,
can grow and remodel in a physiologic manner in parallel with
cardiac and whole body growth (Figure 3) (Bertipaglia et al.,
2003; Scholl et al., 2010).
Which Characteristics Should an Optimal
Bioengineered Graft Have?
The creation of an optimal bioengineered graft relies upon the
careful choice of two main protagonists: (1) the biomaterial and
(2) the cells that will repopulate the biomaterial graft. Scaffolds
used in cardiac surgery should provide structural integrity at
the time of repair, while permitting infiltration of cells from
native tissue and enabling the development of new vessels
and blood supply, which contributes to tissue remodeling. The
cell-scaffold constructs are configured to serve as a template
to promote development of structures that closely mimic the
original tissues (Cheema et al., 2012; Fallahiarezoudar et al.,
2015). Interestingly, physiological cyclic strain and shear stress
may even accelerate the formation of tissue starting from the
cellularized graft (Engelmayr et al., 2006). The final result should
be a new tissue composed entirely of the patient’s autologous cells,
able to remodel in response to physiological changes (Butcher
et al., 2011; Dean et al., 2012). Not less important, an advantage
of coating the prosthetic materials with stem cells or ECs before
transplantation is the prevention of thrombotic complications.
The optimal reparative patch for closure of atrial and
ventricular septal defects and RVOT reconstruction, as well as the
optimal substitutive valves used in pediatric CHD, ideally should
possess the following characteristics (Butcher et al., 2011; Dean
et al., 2012; Kalfa and Bacha, 2013; Alsoufi, 2014):
• absence of immunogenicity,
• growth potential proportional to somatic enlargement,
• excellent durable hemodynamic profile,
• availability in different sizes,
• pliability,
• association with minimal thromboembolism risk thus not
requiring anticoagulation,
• low incidence of structural degeneration,
• resistance to calcification.
These characteristics are critical especially in newborns, in which
corrections should be durable for all the course of a normal
lifespan, to avoid repeated risky operations. But to date, the
optimal scaffold still does not exist, although many progresses
have been done in this direction, and a wide series of biological
and synthetic materials are currently under evaluation in the
attempt to find the optimized one.
An important factor to consider during the creation of a
bioengineered graft is its mechanical behavior. Before proceeding
with any preclinical validation, the performance of bioengineered
grafts is first evaluated ex vivo. This is done both before and
after the seeding of cells, to understand how the cells affect
the matrix remodeling in biological grafts. During these tests,
the hydrodynamics functions and the durability of the graft
are evaluated, both under static conditions and in presence of
pulsatile flow. The elasticity and stiffness of the graft are evaluated
with both uniaxial and biaxial mechanical tests (Ghanbari et al.,
2009).
Adaptability of Currently Available Grafts to
Tissue Engineering
Some undesirable characteristics of currently available grafts
discourage the application in CHD patients, but fortunately
progresses have been done and promising solutions are
underway. The main advantages and disadvantages of
materials used for correction of CHD are recapitulated in
Figure 4.
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FIGURE 3 | Cartoon illustrating the promising strategy of tissue
engineering based on which grafts and materials are combined with
patient autologous cells and grown in vitro or in a bioreactor, in order
to obtain an optimized cellularized graft that lacks of
immunogenicity, thrombogenicity, and risk of calcification, while
having the potential to grow in parallel with the child growth.
One matter of concern is that the toxicity of chemical
agents used during manufacture of prostheses might inhibit the
functionalization by autologous cells. A coating with bioactive
substances has been proposed to overcome the last problem and
promote the process of recellularization in vivo Dohmen et al.,
2006a; Butcher et al., 2011; Strange et al., 2015. Moreover, the
use of glutaraldehyde has been challenged because of concerns
about the promotion of calcification. Calcification of grafts,
in particular valves, is a major problem since it can cause
the failure of the graft and the occurrence of further surgery.
The risk of calcification in children is even higher than in
adults, as in young patients the mobilization of calcium, due
to bone remodeling, accelerates the calcification process. A
possible solution is represented by anti-calcification treatments
(Butcher et al., 2011; Pok and Jacot, 2011). It remains unknown
if calcification may affect cells used for tissue engineering.
This risk may be higher for cells, including MSCs, which
have the propensity to differentiate into osteocytes under
inductive conditions (Ohata and Ozono, 2014). However, it
cannot be excluded that other cell types may not only resist
to xenograft manufacture agents but also contrast their pro-
calcifying action.
The CorMatrix R© ECM (CorMatrix Alpharetta, GA), a patch
made of decellularized porcine small intestinal submucosa
extracellular matrix (SIS-ECM), displays a lot of potential
advantages over other materials currently used in pediatric
cardiac surgery, such as ease handling and implantability,
abundance, low immunogenicity, high mechanical strength,
minimal scar formation, recruitment of host cells, remodeling
without calcification and possible growth potential (Pok and
Jacot, 2011; Kalfa and Bacha, 2013). CorMatrix patches have
been successfully used in congenital heart surgery for pediatric
cardiac and vascular reconstructions (Scholl et al., 2010; Quarti
et al., 2011; Witt et al., 2013). Recently, our group confirmed the
great recellularization properties of the CorMatrix, successfully
growing cardiac pericytes—isolated from children affected by
CHD—onto CorMatrix patches up to 3 weeks in a bioreactor,
finally showing the engraftment and viability of cells (Avolio et al.,
2015b).
Recently, scaffolds have been fabricated using synthetic
biodegradable polymers, such as polyglicolyc acid (PGA), poly-L-
lactic acid (PLLA) and polycaprolactone (PCL). On one hand, the
advantages of using these polymers are a limitless supply, ease
of shaping, and the possibility to combine the concentrations
of the polymers to generate scaffolds that meet the compliance
specifications of the environment in which they have to be
introduced. But on the other hand, the degradation process by
hydrolysis will affect the mechanical properties over time. The
degradation rates have been estimated in 2–3 months for PGA
and 2 and 3 years for PLLA and PCL, respectively. Although
some concerns have been reported about the cytotoxicity of the
products of the degradation process (Butcher et al., 2011; Dean
et al., 2012; Fallahiarezoudar et al., 2015), these materials are
currently the most used in tissue-engineering procedures for
the construction of autologous grafts made by the patient’s own
tissue.
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FIGURE 4 | Schematic cartoon summarizing the main advantages and disadvantages of using the different synthetic or biological materials and grafts
for surgical correction of CHD in children.
Methods of Cell Seeding and Growth of Tissues
In Vitro
During the generation of a bioengineered graft, not only the
selection of the proper cell type and the choice of a physiological
culture method are crucial in order to achieve good results, but
also cell seeding is one of the key issues. How to seed cells
efficiently and uniformly, especially in the inner parts of scaffolds
with pores, and with no impairment to the cells, has been one of
the major challenges for tissue engineering.
Since from the beginning, static seeding has been the most
frequently used because of its simplicity and the ease to be
performed within a common cell culture laboratory, since it does
not require sophisticated equipment. However, the efficiency of
static seeding is always low, and the distribution of the cells
throughout the scaffold is not uniform, with the inner part of
the scaffold holding few cells, even if excellent biocompatible
scaffolds with big pores are used. As a consequence, only the
superficial layer of the scaffold will be formed by the regenerated
tissue (Dai et al., 2009).
One important factor that limits the penetration of cells inside
the scaffold is represented by air in the pores, which explains
why static seeding cannot reach satisfactory results in term of
scaffold repopulation. Different solutions have been considered
to overcome this bottleneck.
In centrifugation seeding, a moderate centrifugal force is
applied during the seeding process, to facilitate the penetration
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of cells in the central part of the scaffold (Godbey et al.,
2004; Roh et al., 2007). However, whether survived cells
remain functional after centrifugation has still to be determined.
Moreover, during centrifugation the orientation of the scaffold
cannot be controlled, thus that the overlapping of material pieces
does not allow a homogeneous distribution of cells. Instead,
the low-pressure seeding uses a vacuum desiccator to create a
reduced pressure that draws the air in the materials out by
pressure difference, facilitating the penetration of the culture
media and cells inside the pores (Torigoe et al., 2007). However,
despite the seeding efficiency is increased, the low pressure may
affect cell viability and function after seeding, thus additional
investigations are required (Dai et al., 2009). In perfusion seeding,
a continuous cell suspension perfusion is applied through 3D-
scaffold pores using bioreactors to assist in cell infiltration and to
aid in nutrition (Dai et al., 2009).
A bioreactor is a device able to ensure the biological and
physiological environment of the heart and the circulatory
system. Mimicking the physiological mechanical forces, shear
stress and blood flow, the bioreactor can allow the construction of
engineered scaffolds that will be functional after transplantation
into the patients (Carrier et al., 1999; Hecker and Birla, 2007).
When cellularized scaffolds are kept in culture for long time,
the tissue grows and reaches a 3D-structure, so that the static
culture system is not adequate to guarantee the perfusion of
culture media uniformly. A solution to this problem comes
from the dynamic bioreactors, which can maintain viability
of tissue-engineered organs by using both mechanical and
biochemical conditioning. Apart the basic requirements of cell
cultures—which include the control over the time of dissolved
O2 and CO2, pH, temperature and nutrients concentration—a
dynamic bioreactor can provide the control of flow waveform
and physiological pressure, keeping culture medium under the
pulsatile flow that enables the perfusion of the media inside the
entire graft and simulates at the same time the in vivo pressure
and heart rate (Carrier et al., 1999; Hecker and Birla, 2007).
Preclinical Studies and Clinical Application of
Tissue Engineered-grafts
Tissue engineering-based grafts have been tested in small and
large animal models to assess their safety and feasibility before
translation to clinics. So far, BMMNCs and ECs have been
frequently selected for preclinical studies of tissue engineering
applications, probably due to the relative ease of harvesting BM
aspirates and peripheral veins compared, for example, to samples
of cardiac source. For the sake of brevity and clarity, main animal
studies are summarized in Table 1. During these procedures,
scaffolds were firstly seeded with cells in vitro, and secondly
implanted into the animals. The results obtained with animals
encouraged the test in humans.
Positive results have been obtained also from clinical studies
involving the application of tissue engineering-based grafts in
children affected by CHD, although they are still limited to few
reports. In 2001, the transplantation of a tissue engineering-
based graft on a 4-years-old girl with univentricular heart
and pulmonary atresia was recorded. Autologous cells were
isolated from a peripheral vein and seeded onto a biodegradable
tubular scaffold composed by PLLA/PCL reinforced with PGA,
designed in order to degrade within 8 weeks. Seven months
after implantation, the conduit was not occluded and there was
no evidence of aneurysm (Shin’oka et al., 2001). Two years
later the same group reported other clinical cases of children
with CHD who received a biodegradable tissue engineering-
based graft (PLLA/PCL, designed to be degraded in 3–5 years)
seeded with total BMCs or selected BMMNCs. Again, the
results were positive, with no stenosis documented in the grafts
(Matsumura et al., 2003a). The successful transplantation of
a vascular biodegradable conduit (PLLA/PCL reinforced with
PGA) seeded with saphenous vein derived cells was recorded in
a 12-years-old during the Fontan operation (Naito et al., 2003).
Later, the clinical results of the application of tissue engineering-
based grafts seeded with autologous BMCs in CHD patients
(25 out of 42 patients recruited were <7 years) were published
(Shin’oka et al., 2005). The scaffolds were made by PLLA/PCL
and PGA, degradable in 2 years. The results were positive,
without thrombosis, stenosis or obstruction of the grafts after a
median of 16 months; grafts remained patent and their diameter
increased in size (Shin’oka et al., 2005). More recently, a similar
study was conducted in patients with single ventricle physiology
(17 out of 25 patients recruited were <7 years), in which
PLLA/PCL/PGA grafts seeded with autologous BMMNCs were
implanted as extracardiac cavopulmonary conduits. Four out of
25 patients presented graft obstruction that required angioplasty,
but all the other patients experimented a good recovery without
failure of the graft (Hibino et al., 2010).
Despite these first encouraging results, the performance of TE-
grafts in CHD children still needs to be investigated, since a main
limitation of the studies performed so far is the lack of a long
term follow-up. Nevertheless, application of tissue engineering-
based grafts to the correction of CHD is still a new field of study,
which will be extensively expanded in the coming future.
Future Perspectives
The choice of the appropriate cell type to use for cell therapy
is of crucial importance to reach the desired therapeutic goal.
In the future, cell types able to guarantee on the one hand the
regeneration of the missing or lost tissue, and on the other
hand the parallel remodeling of the extracellular matrix in order
to provide the new generated tissue with the ability to adapt
with the anatomy of the growing cardiovascular system, might
be privileged; also, combinatory cell products may represent
an interesting and safe option. But, while there is space for
improvement in the characterization and quality of the cell
product, the field of regenerative medicine for treatment of
CHD urgently requires tissue engineering solutions, as dispersed
cells are not ideal to reconstruct valves and conduits. To date,
one major limitation in the use of prosthetic devices is the
need of replacement. Research is currently underway to provide
biologically compatible solutions. While there is a remarkably
growing interest in possibilities offered by cell therapy and tissue
engineering, the clinical application in newborns and children is
still in its pioneering phase.
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TABLE 1 | Preclinical studies with tissue-engineered grafts.
Study Animal model Cells seeded Scaffold used Outcome
Matsumura
et al., 2003b
Dog Allogenic BMMNCs Copolymer of LA/CL
covered by PLLA
TE-grafts were implanted into the vena cava. After up to 8 weeks, no
stenosis was observed and cells on the grafts expressed endothelial
and VSMc markers
Vincentelli
et al., 2007
Lamb Allogenic BMMNCs
or MSCs
Decellularized
porcine pulmonary
conduits
TE-grafts were implanted into the pulmonary artery. After 4 months,
both the valves were recolonized and re-endothe-lialized.
BMMNC-valves were thicker and showed inflammatory cell infiltration,
while MSC-valves displayed extracellular matrix and cell disposition
close to those of native pulmonary valves
Brennan
et al., 2008
Lamb Autologous
BMMNCs
PGA scaffolds
covered by LA/CL
TE-grafts implanted as inferior vena cava (IVC) interposition grafts. After
6 months, grafts were patent and increased in volume, with no
evidence of aneurysmal dilatation. They were histologically comparable
to the native IVC
Roh et al.,
2010
SCID/beige mice Xenogenic human
BMMNCs
PGA scaffolds
covered by LA/CL
TE-grafts were implanted as inferior vena cava interposition grafts. After
24 weeks the original scaffold was degraded and substituted by
organized layers of ECM, endothelial and smooth muscle cells,
resembling the native IVC
Sutherland
et al., 2005
Sheep Autologous
BM-MSCs
PGA/PLLA The pulmonary valve was resected and TE-valve was implanted into
the pulmonary artery. After 4 and 8 months grafts were histologically
comparable to the native valve
Shinoka et al.,
1995
Lamb Allogenic ovine
artery fibroblasts
and ECs
PGA leaflets The right posterior leaflet of the pulmonary valve was resected and
replaced with a TE-valve leaflet. Absence of stenosis. Development of
ECM with appropriate cellular architecture
Dohmen
et al., 2006b
Sheep Autologous ECs
from jugular vein
Decellularized valve Scaffold was implanted into the RVOT. After 6 months, there was no
calcification, and histologically ECs and fibroblasts were observed
He et al.,
2010
Rat Xenogenic human
skeletal muscle
pericytes
Poly(ester-urethane)
urea scaffolds
TE-grafts were implanted end-to-end into the abdominal aorta. After 8
weeks, pericytes evenly populated the graft. TE-grafts presented
extensive tissue remodeling with organized layers of endothelial and
smooth muscle cells, and collagen and elastin, resembling the native
arterial conduit
Cell therapy products or tissue-engineered products are
classified as advanced therapy medicinal products (ATMP)
that need to be authorized through centralized procedures.
In a tissue-engineered product both components (the scaffold
and cell product) must be GMP grade and the combination
of the two should be also GMP certified. This includes the
manufacture and expansion of cells in the scaffold prior
implantation, demonstration of conserved mechanical properties
and safety/efficacy in adequate animal models. Therefore,
it is likely that the first products to become available for
clinical experimentation will be those made by clinical grafts
containing cells that have been already tested in clinical
trials. In term of safety, it should be kept in mind that
CHD is increasingly acknowledged to be associated with
genetic polymorphisms. Whether alterations in the genetic
program that controls the proper formation of the heart
may influence stem cell behavior remains unknown and may
represent an additional challenge for the progress of the
field.
Advancements in diagnostic screening allow an early
diagnosis of CHD and set the basis for guiding the best
reconstructive strategy as illustrated in Figure 5. In the first
scenario, cells are obtained prenatally or at birth with minimally
invasive procedures, expanded, incorporated in scaffolds ready
for use in definitive surgical correction without need of palliative
procedures. Induced pluripotent cells could be ideally generated
to this purpose. Alternatively, cord cells have a potential for
cases that do not require an immediate intervention at birth.
In the second scenario, when diagnosis is made post-natally,
stem cells from remnants of palliative surgery could be expanded
in vitro and combined with biomaterials using bioengineering
techniques; afterwards, the resulting cellularized graft will be
surgically implanted into the diseased heart at the occasion of a
second open-chest surgery, helping the surgeon in performing
the reconstructive procedures required to manage complex
CHD. Looking at the best cell type, the use of stem cells
from cardiac source may give the advantage of a physiological
commitment to originate all the 3 major cell types of the
heart: cardiomyocytes, ECs and VSMCs. Additional cells with
complementary activities, namely vascular cells and pericytes
could be added in a combinatory approach.
In conclusion, the potential of tissue engineering may provide
in the next future definitive solutions for correction of CHD
in newborns and children, opening new avenues with immense
therapeutic benefits.
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FIGURE 5 | Cartoon illustrating possible future strategies for the
surgical management of newborns with CHD. If CHD is diagnosed
prenatally, foetal cells may be harvested and iPS generated; as an
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birth. When diagnosis of CHD is made after birth or in babies who
require a palliative surgical operation soon after birth, stem cells may be
isolated from surgical cardiac leftovers. All these types of cells will allow
the generation of a tissue-engineered graft endowed with growth and
remodeling potential, necessary for the definitive correction of cardiac
defects.
the literature, drafted and critically revised the manuscript.
All the authors have approved the final submission of the
manuscript.
Acknowledgments
This work was supported by (1) manufacture scale up of
human pericyte progenitor cells for regenerative medicine, MRC
Translational Stem Cell Research Grant; (2) Bristol Biomedical
Research Unit in Cardiovascular Disease (lead for Regenerative
Medicine workpackage), National Institute Health Research
Biomedical Research Unit (NIHR BRU); (3) preclinical trial
with human pericyte progenitors in a large animal model of
myocardial infarction, BHF special project grant; (4) BHF Centre
of RegenerativeMedicine; and (5) the Sir Jules Thorn award 2014.
Figures 1, 2, 5 have been prepared using SERVIER Medical Art.
References
Al-Halees, Z., Pieters, F., Qadoura, F., Shahid, M., Al-Amri, M., and Al-Fadley,
F. (2002). The Ross procedure is the procedure of choice for congenital aortic
valve disease. J. Thorac. Cardiovasc. Surg. 123, 437–441. discussion: 441–432.
doi: 10.1067/mtc.2002.119705
Alsoufi, B. (2014). Aortic valve replacement in children: options and outcomes.
J. Saudi Heart Assoc. 26, 33–41. doi: 10.1016/j.jsha.2013.11.003
Amir, G., Ma, X., Reddy, V. M., Hanley, F. L., Reinhartz, O., Ramamoorthy,
C., et al. (2008). Dynamics of human myocardial progenitor cell
populations in the neonatal period. Ann. Thorac. Surg. 86, 1311–1319.
doi: 10.1016/j.athoracsur.2008.06.058
Avolio, E., Meloni, M., Spencer, H. L., Riu, F., Katare, R., Mangialardi,
G., et al. (2015a). Combined intramyocardial delivery of human
pericytes and cardiac stem cells additively improves the healing of
mouse infarcted hearts through stimulation of vascular and muscular
repair. Circ. Res. 116, e81–e94. doi: 10.1161/CIRCRESAHA.115.
306146
Avolio, E., Rodriguez-Arabaolaza, I., Spencer, H., Riu, F., Mangialardi, G., Slater,
S., et al. (2015b). Expansion and characterization of neonatal cardiac pericytes
provides a novel cellular option for tissue engineering in congenital heart
disease. J. Am. Heart Assoc. 4:e002043. doi: 10.1161/JAHA.115.002043
Badylak, S. F., Weiss, D. J., Caplan, A., and Macchiarini, P. (2012). Engineered
whole organs and complex tissues. Lancet 379, 943–952. doi: 10.1016/S0140-
6736(12)60073-7
Balsam, L. B., Wagers, A. J., Christensen, J. L., Kofidis, T., Weissman, I. L., and
Robbins, R. C. (2004). Haematopoietic stem cells adopt mature haematopoietic
fates in ischaemic myocardium. Nature 428, 668–673. doi: 10.1038/nature
02460
Barron, D. J., Kilby, M. D., Davies, B., Wright, J. G., Jones, T. J., and Brawn,
W. J. (2009). Hypoplastic left heart syndrome. Lancet 374, 551–564. doi:
10.1016/S0140-6736(09)60563-8
Baumgartner, H., Bonhoeffer, P., De Groot, N. M., de Haan, F., Deanfield, J.
E., Galie, N., et al. (2010). ESC Guidelines for the management of grown-up
congenital heart disease (new version 2010). Eur. Heart J. 31, 2915–2957. doi:
10.1093/eurheartj/ehq249
Bearzi, C., Rota, M., Hosoda, T., Tillmanns, J., Nascimbene, A., De Angelis, A.,
et al. (2007). Human cardiac stem cells. Proc. Natl. Acad. Sci. U.S.A. 104,
14068–14073. doi: 10.1073/pnas.0706760104
Beitnes, J. O., Hopp, E., Lunde, K., Solheim, S., Arnesen, H., Brinchmann,
J. E., et al. (2009). Long-term results after intracoronary injection of
autologous mononuclear bone marrow cells in acute myocardial infarction:
the ASTAMI randomised, controlled study. Heart 95, 1983–1989. doi:
10.1136/hrt.2009.178913
Frontiers in Cell and Developmental Biology | www.frontiersin.org 13 June 2015 | Volume 3 | Article 39
Avolio et al. Tissue engineering for CHD correction
Beltrami, A., Cesselli, D., and Beltrami, C. (2011). “Multiple sources for cardiac
stem cells and their cardiogenic potential,” in Regenerating the Heart, eds I. S.
Cohen and G. R. Gaudette (New York, NY: Humana Press), 149–171.
Bergmane, I., Lacis, A., Lubaua, I., Jakobsons, E., and Erglis, A. (2013). Follow-
up of the patients after stem cell transplantation for pediatric dilated
cardiomyopathy. Pediatr. Transplant. 17, 266–270. doi: 10.1111/petr.12055
Bergmann, O., Bhardwaj, R. D., Bernard, S., Zdunek, S., Barnabe-Heider, F.,Walsh,
S., et al. (2009). Evidence for cardiomyocyte renewal in humans. Science 324,
98–102. doi: 10.1126/science.1164680
Bernstein, H. S., and Srivastava, D. (2012). Stem cell therapy for cardiac disease.
Pediatr. Res. 71(4 Pt 2), 491–499. doi: 10.1038/pr.2011.61
Bertipaglia, B., Ortolani, F., Petrelli, L., Gerosa, G., Spina, M., Pauletto, P.,
et al. (2003). Cell characterization of porcine aortic valve and decellularized
leaflets repopulated with aortic valve interstitial cells: the VESALIO Project
(Vitalitate Exornatum Succedaneum Aorticum Labore Ingenioso Obtenibitur).
Ann. Thorac. Surg. 75, 1274–1282. doi: 10.1016/S0003-4975(02)04706-9
Bolli, R., Chugh, A. R., D’Amario, D., Loughran, J. H., Stoddard, M. F., Ikram,
S., et al. (2011). Cardiac stem cells in patients with ischaemic cardiomyopathy
(SCIPIO): initial results of a randomised phase 1 trial. Lancet 378, 1847–1857.
doi: 10.1016/S0140-6736(11)61590-0
Brennan, M. P., Dardik, A., Hibino, N., Roh, J. D., Nelson, G. N., Papademitris, X.,
et al. (2008). Tissue-engineered vascular grafts demonstrate evidence of growth
and development when implanted in a juvenile animal model. Ann. Surg. 248,
370–377. doi: 10.1097/sla.0b013e318184dcbd
Burkhart, H. M., Qureshi, M. Y., Peral, S. C., O’Leary, P. W., Olson, T. M., Cetta,
F., et al. (2015). Regenerative therapy for hypoplastic left heart syndrome:
first report of intraoperative intramyocardial injection of autologous umbilical-
cord blood-derived cells. J. Thorac. Cardiovasc. Surg. 149, e35–e37. doi:
10.1016/j.jtcvs.2014.10.093
Butcher, J. T., Mahler, G. J., and Hockaday, L. A. (2011). Aortic valve disease and
treatment: the need for naturally engineered solutions. Adv. Drug Deliv. Rev.
63, 242–268. doi: 10.1016/j.addr.2011.01.008
Cantero Peral, S., Burkhart, H. M., Oommen, S., Yamada, S., Nyberg, S. L., Li,
X., et al. (2015). Safety and feasibility for pediatric cardiac regeneration using
epicardial delivery of autologous umbilical cord blood-derived mononuclear
cells established in a porcine model system. Stem Cells Transl. Med. 4, 195–206.
doi: 10.5966/sctm.2014-0195
Carrier, R. L., Papadaki, M., Rupnick, M., Schoen, F. J., Bursac, N., Langer, R.,
et al. (1999). Cardiac tissue engineering: cell seeding, cultivation parameters,
and tissue construct characterization. Biotechnol. Bioeng. 64, 580–589.
Castro-Manrreza, M. E., and Montesinos, J. J. (2015). Immunoregulation
by mesenchymal stem cells: biological aspects and clinical applications.
J. Immunol. Res. 2015:394917. doi: 10.1155/2015/394917
Cebotari, S., Tudorache, I., Ciubotaru, A., Boethig, D., Sarikouch, S., Goerler,
A., et al. (2011). Use of fresh decellularized allografts for pulmonary
valve replacement may reduce the reoperation rate in children and
young adults: early report. Circulation 124(11 Suppl.), S115–S123. doi:
10.1161/CIRCULATIONAHA.110.012161
Cheema, F. H., Polvani, G., Argenziano, M., and Pesce, M. (2012). Combining
stem cells and tissue engineering in cardiovascular repair – a step
forward to derivation of novel implants with enhanced function and self-
renewal characteristics. Recent Pat. Cardiovasc. Drug Discov. 7, 10–20. doi:
10.2174/157489012799362403
Chen, M. Y., Lie, P. C., Li, Z. L., and Wei, X. (2009). Endothelial differentiation
of Wharton’s jelly-derived mesenchymal stem cells in comparison with bone
marrow-derived mesenchymal stem cells. Exp. Hematol. 37, 629–640. doi:
10.1016/j.exphem.2009.02.003
Chen, W. C., Baily, J. E., Corselli, M., Diaz, M. E., Sun, B., Xiang, G., et al. (2015).
Human myocardial pericytes: multipotent mesodermal precursors exhibiting
cardiac specificity. Stem Cells 33, 557–573. doi: 10.1002/stem.1868
Cushing, M. C., Jaeggli, M. P., Masters, K. S., Leinwand, L. A., and Anseth, K.
S. (2005). Serum deprivation improves seeding and repopulation of acellular
matrices with valvular interstitial cells. J. Biomed. Mater. Res. A 75, 232–241.
doi: 10.1002/jbm.a.30412
da Costa, F. D., Dohmen, P. M., Duarte, D., von Glenn, C., Lopes, S. V., Filho,
H. H., et al. (2005). Immunological and echocardiographic evaluation of
decellularized versus cryopreserved allografts during the Ross operation. Eur.
J. Cardiothorac. Surg. 27, 572–578. doi: 10.1016/j.ejcts.2004.12.057
Dai, W., Dong, J., Chen, G., and Uemura, T. (2009). Application of low-pressure
cell seeding system in tissue engineering. Biosci. Trends 3, 216–219.
Davies, B., Elwood, N. J., Li, S., Cullinane, F., Edwards, G. A., Newgreen, D. F.,
et al. (2010). Human cord blood stem cells enhance neonatal right ventricular
function in an ovine model of right ventricular training. Ann. Thorac. Surg. 89,
585–593, e581–e584. doi: 10.1016/j.athoracsur.2009.10.035
Dean, E. W., Udelsman, B., and Breuer, C. K. (2012). Current advances in
the translation of vascular tissue engineering to the treatment of pediatric
congenital heart disease. Yale J. Biol. Med. 85, 229–238.
Dimarino, A. M., Caplan, A. I., and Bonfield, T. L. (2013). Mesenchymal stem cells
in tissue repair. Front. Immunol. 4:201. doi: 10.3389/fimmu.2013.00201
Dixon, J. A., Gorman, R. C., Stroud, R. E., Bouges, S., Hirotsugu, H., Gorman,
J. H. III, et al. (2009). Mesenchymal cell transplantation and myocardial
remodeling after myocardial infarction. Circulation 120(11 Suppl.), S220–S229.
doi: 10.1161/CIRCULATIONAHA.108.842302
Dohmen, P. M., da Costa, F., Holinski, S., Lopes, S. V., Yoshi, S., Reichert, L. H.,
et al. (2006a). Is there a possibility for a glutaraldehyde-free porcine heart valve
to grow? Eur. Surg. Res. 38, 54–61. doi: 10.1159/000091597
Dohmen, P. M., da Costa, F., Yoshi, S., Lopes, S. V., da Souza, F. P., Vilani, R., et al.
(2006b). Histological evaluation of tissue-engineered heart valves implanted in
the juvenile sheep model: is there a need for in-vitro seeding? J. Heart Valve Dis.
15, 823–829.
Dohmen, P. M., Lembcke, A., Hotz, H., Kivelitz, D., and Konertz, W. F. (2002).
Ross operation with a tissue-engineered heart valve. Ann. Thorac. Surg. 74,
1438–1442. doi: 10.1016/S0003-4975(02)03881-X
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause,
D., et al. (2006). Minimal criteria for defining multipotent mesenchymal
stromal cells. The International Society for Cellular Therapy position
statement. Cytotherapy 8, 315–317. doi: 10.1080/14653240600855905
Engelmayr, G. C. Jr., Sales, V, L., Mayer, J. E. Jr., and Sacks, M. S. (2006).
Cyclic flexure and laminar flow synergistically accelerate mesenchymal stem
cell-mediated engineered tissue formation: implications for engineered heart
valve tissues. Biomaterials 27, 6083–6095. doi: 10.1016/j.biomaterials.2006.
07.045
Fallahiarezoudar, E., Ahmadipourroudposht, M., Idris, A., and Mohd Yusof, N.
(2015). A review of: application of synthetic scaffold in tissue engineering
heart valves. Mater. Sci. Eng. C Mater. Biol. Appl. 48, 556–565. doi:
10.1016/j.msec.2014.12.016
Frescura, C., and Thiene, G. (2014). The new concept of univentricular heart.
Front. Pediatr. 2:62. doi: 10.3389/fped.2014.00062
Gabbieri, D., Dohmen, P. M., Linneweber, J., Lembcke, A., Braun, J. P., and
Konertz, W. (2007). Ross procedure with a tissue-engineered heart valve in
complex congenital aortic valve disease. J. Thorac. Cardiovasc. Surg. 133,
1088–1089. doi: 10.1016/j.jtcvs.2006.12.023
Geva, T., Martins, J. D., and Wald, R. M. (2014). Atrial septal defects. Lancet 383,
1921–1932. doi: 10.1016/S0140-6736(13)62145-5
Ghanbari, H., Viatge, H., Kidane, A. G., Burriesci, G., Tavakoli, M., and Seifalian,
A. M. (2009). Polymeric heart valves: new materials, emerging hopes. Trends
Biotechnol. 27, 359–367. doi: 10.1016/j.tibtech.2009.03.002
Gnecchi, M., Danieli, P., and Cervio, E. (2012). Mesenchymal stem cell therapy
for heart disease. Vascul. Pharmacol. 57, 48–55. doi: 10.1016/j.vph.2012.
04.002
Gnecchi, M., He, H., Noiseux, N., Liang, O. D., Zhang, L., Morello, F., et al. (2006).
Evidence supporting paracrine hypothesis for Akt-modifiedmesenchymal stem
cell-mediated cardiac protection and functional improvement. FASEB J. 20,
661–669. doi: 10.1096/fj.05-5211com
Godbey, W. T., Hindy, S. B., Sherman, M. E., and Atala, A. (2004). A novel
use of centrifugal force for cell seeding into porous scaffolds. Biomaterials 25,
2799–2805. doi: 10.1016/j.biomaterials.2003.09.056
Gossl, M., Khosla, S., Zhang, X., Higano, N., Jordan, K. L., Loeﬄer, D., et al. (2012).
Role of circulating osteogenic progenitor cells in calcific aortic stenosis. J. Am.
Coll. Cardiol. 60, 1945–1953. doi: 10.1016/j.jacc.2012.07.042
He, W., Nieponice, A., Soletti, L., Hong, Y., Gharaibeh, B., Crisan, M., et al.
(2010). Pericyte-based human tissue engineered vascular grafts. Biomaterials
31, 8235–8244. doi: 10.1016/j.biomaterials.2010.07.034
Hecker, L., and Birla, R. K. (2007). Engineering the heart piece by piece:
state of the art in cardiac tissue engineering. Regen. Med. 2, 125–144. doi:
10.2217/17460751.2.2.125
Frontiers in Cell and Developmental Biology | www.frontiersin.org 14 June 2015 | Volume 3 | Article 39
Avolio et al. Tissue engineering for CHD correction
Henaine, R., Roubertie, F., Vergnat, M., and Ninet, J. (2012). Valve replacement in
children: a challenge for a whole life. Arch. Cardiovasc. Dis. 105, 517–528. doi:
10.1016/j.acvd.2012.02.013
Hibino, N., McGillicuddy, E., Matsumura, G., Ichihara, Y., Naito, Y., Breuer,
C., et al. (2010). Late-term results of tissue-engineered vascular grafts
in humans. J. Thorac. Cardiovasc. Surg. 139, 431–436, e431–e432. doi:
10.1016/j.jtcvs.2009.09.057
Hoashi, T., Matsumiya, G., Miyagawa, S., Ichikawa, H., Ueno, T., Ono, M., et al.
(2009). Skeletal myoblast sheet transplantation improves the diastolic function
of a pressure-overloaded right heart. J. Thorac. Cardiovasc. Surg. 138, 460–467.
doi: 10.1016/j.jtcvs.2009.02.018
Hosoda, T., Kajstura, J., Leri, A., and Anversa, P. (2010). Mechanisms of
myocardial regeneration. Circ. J. 74, 13–17. doi: 10.1253/circj.CJ-09-0665
Hsieh, P. C., Segers, V. F., Davis, M. E., MacGillivray, C., Gannon, J., Molkentin,
J. D., et al. (2007). Evidence from a genetic fate-mapping study that stem cells
refresh adult mammalian cardiomyocytes after injury. Nat. Med. 13, 970–974.
doi: 10.1038/nm1618
Hsu, D. T., and Lamour, J. M. (2015). Changing indications for pediatric heart
transplantation: complex congenital heart disease. Circulation 131, 91–99. doi:
10.1161/CIRCULATIONAHA.114.001377
Ibrahim, A. G., Cheng, K., and Marban, E. (2014). Exosomes as critical agents of
cardiac regeneration triggered by cell therapy. Stem Cell Rep. 2, 606–619. doi:
10.1016/j.stemcr.2014.04.006
Invernici, G., Emanueli, C., Madeddu, P., Cristini, S., Gadau, S., Benetti, A.,
et al. (2007). Human fetal aorta contains vascular progenitor cells capable
of inducing vasculogenesis, angiogenesis, and myogenesis in vitro and in a
murine model of peripheral ischemia. Am. J. Pathol. 170, 1879–1892. doi:
10.2353/ajpath.2007.060646
Ishigami, S., Ohtsuki, S., Tarui, S., Ousaka, D., Eitoku, T., Kondo, M., et al.
(2015). Intracoronary autologous cardiac progenitor cell transfer in patients
with hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled
trial. Circ. Res. 116, 653–664. doi: 10.1161/CIRCRESAHA.116.304671
Kalfa, D., and Bacha, E. (2013). New technologies for surgery of the
congenital cardiac defect. Rambam Maimonides Med. J. 4:e0019. doi:
10.5041/RMMJ.10119
Kawada, H., Fujita, J., Kinjo, K., Matsuzaki, Y., Tsuma, M., Miyatake, H.,
et al. (2004). Nonhematopoietic mesenchymal stem cells can be mobilized
and differentiate into cardiomyocytes after myocardial infarction. Blood 104,
3581–3587. doi: 10.1182/blood-2004-04-1488
Khoshnood, B., Lelong, N., Houyel, L., Thieulin, A. C., Jouannic, J. M., Magnier,
S., et al. (2012). Prevalence, timing of diagnosis and mortality of newborns with
congenital heart defects: a population-based study. Heart 98, 1667–1673. doi:
10.1136/heartjnl-2012-302543
Klemmt, P. A., Vafaizadeh, V., and Groner, B. (2011). The potential of amniotic
fluid stem cells for cellular therapy and tissue engineering. Expert Opin. Biol.
Ther. 11, 1297–1314. doi: 10.1517/14712598.2011.587800
Krause, K., Schneider, C., Kuck, K. H., and Jaquet, K. (2010). Stem cell therapy in
cardiovascular disorders. Cardiovasc. Ther. 28, e101–e110. doi: 10.1111/j.1755-
5922.2010.00208.x
Lambert, V., Gouadon, E., Capderou, A., Le Bret, E., Ly, M., Dinanian, S., et al.
(2015). Right ventricular failure secondary to chronic overload in congenital
heart diseases: benefits of cell therapy using human embryonic stem cell-
derived cardiac progenitors. J. Thorac. Cardiovasc. Surg. 149, 708–715, e701.
doi: 10.1016/j.jtcvs.2014.11.033
Lundy, S. D., Zhu, W. Z., Regnier, M., and Laflamme, M. A. (2013). Structural
and functional maturation of cardiomyocytes derived from human pluripotent
stem cells. Stem Cells Dev. 22, 1991–2002. doi: 10.1089/scd.2012.0490
Macchiarini, P., Jungebluth, P., Go, T., Asnaghi, M. A., Rees, L. E., Cogan, T. A.,
et al. (2008). Clinical transplantation of a tissue-engineered airway. Lancet 372,
2023–2030. doi: 10.1016/S0140-6736(08)61598-6
Madonna, R., and De Caterina, R. (2015). Circulating endothelial progenitor
cells: do they live up to their name? Vascul. Pharmacol. 67–69, 2–5. doi:
10.1016/j.vph.2015.02.018
Makkar, R. R., Smith, R. R., Cheng, K., Malliaras, K., Thomson, L. E., Berman, D.,
et al. (2012). Intracoronary cardiosphere-derived cells for heart regeneration
after myocardial infarction (CADUCEUS): a prospective, randomised phase 1
trial. Lancet 379, 895–904. doi: 10.1016/S0140-6736(12)60195-0
Matsumura, G., Hibino, N., Ikada, Y., Kurosawa, H., and Shin’oka T. (2003a).
Successful application of tissue engineered vascular autografts: clinical
experience. Biomaterials 24, 2303–2308. doi: 10.1016/S0142-9612(03)00043-7
Matsumura, G., Miyagawa-Tomita, S. T., Shin’oka, Ikada, Y., and Kurosawa, H.
(2003b). First evidence that bone marrow cells contribute to the construction of
tissue-engineered vascular autografts in vivo. Circulation 108, 1729–1734. doi:
10.1161/01.CIR.0000092165.32213.61
Mayshar, Y., Ben-David, U., Lavon, N., Biancotti, J. C., Yakir, B., Clark, A. T.,
et al. (2010). Identification and classification of chromosomal aberrations
in human induced pluripotent stem cells. Cell Stem Cell 7, 521–531. doi:
10.1016/j.stem.2010.07.017
Messina, E., De Angelis, L., Frati, G., Morrone, S., Chimenti, S., Fiordaliso, F., et al.
(2004). Isolation and expansion of adult cardiac stem cells from human and
murine heart.Circ. Res. 95, 911–921. doi: 10.1161/01.RES.0000147315.71699.51
Mirensky, T. L., and Breuer, C. K. (2008). The development of tissue-engineered
grafts for reconstructive cardiothoracic surgical applications. Pediatr. Res. 63,
559–568. doi: 10.1203/01.pdr.0000305938.92695.b9
Mishra, R., Vijayan, K., Colletti, E. J., Harrington, D. A., Matthiesen, T. S.,
Simpson, D., et al. (2011). Characterization and functionality of cardiac
progenitor cells in congenital heart patients. Circulation 123, 364–373. doi:
10.1161/CIRCULATIONAHA.110.971622
Muller, P., Pfeiffer, P., Koglin, J., Schafers, H. J., Seeland, U., Janzen,
I., et al. (2002). Cardiomyocytes of noncardiac origin in myocardial
biopsies of human transplanted hearts. Circulation 106, 31–35. doi:
10.1161/01.CIR.0000022405.68464.CA
Murry, C. E., Soonpaa, M. H., Reinecke, H., Nakajima, H., Nakajima, H. O.,
Rubart, M., et al. (2004). Haematopoietic stem cells do not transdifferentiate
into cardiac myocytes in myocardial infarcts. Nature 428, 664–668, doi:
10.1038/nature02446
Naito, Y., Imai, Y. T., Shin’oka, Kashiwagi, J., Aoki, M., Watanabe, M., et al. (2003).
Successul clinical application of tissue-engineered graft for extracardiac Fontan
operation. J. Thorac. Cardiovasc. Surg. 125, 419–420. doi: 10.1067/mtc.2003.134
Neumann, A., Cebotari, S., Tudorache, I., Haverich, A., and Sarikouch, S. (2013).
Heart valve engineering: decellularized allograft matrices in clinical practice.
Biomed. Tech. (Berl). 58, 453–456. doi: 10.1515/bmt-2012-0115
Ohata, Y., and Ozono, K. (2014). Bone and Stem Cells. The mechanism of
osteogenic differentiation from mesenchymal stem cell. Clin. Calcium 24,
501–508. doi: CliCa1404501508
Pasquali, S. K., Shera, D., Wernovsky, G., Cohen, M. S., Tabbutt, S., Nicolson, S.,
et al. (2007). Midterm outcomes and predictors of reintervention after the Ross
procedure in infants, children, and young adults. J. Thorac. Cardiovasc. Surg.
133, 893–899. doi: 10.1016/j.jtcvs.2006.12.006
Peral, S. C., Burkhart, H. M., and Nelson, T. J. (2014). Utilization of stem cells to
treat congenital heart disease: hype and hope. Curr. Opin. Pediatr. 26, 553–560.
doi: 10.1097/MOP.0000000000000138
Perri, G., Polito, A., Esposito, C., Albanese, S. B., Francalanci, P., Pongiglione,
G., et al. (2012). Early and late failure of tissue-engineered pulmonary valve
conduits used for right ventricular outflow tract reconstruction in patients
with congenital heart disease. Eur. J. Cardiothorac. Surg. 41, 1320–1325. doi:
10.1093/ejcts/ezr221
Pincott, E. S., and Burch, M. (2012). Potential for stem cell use in congenital heart
disease. Future Cardiol. 8, 161–169. doi: 10.2217/fca.12.13
Pok, S., and Jacot, J. G. (2011). Biomaterials advances in patches for congenital
heart defect repair. J. Cardiovasc. Transl. Res. 4, 646–654. doi: 10.1007/s12265-
011-9289-8
Quaini, F., Urbanek, K., Beltrami, A. P., Finato, N., Beltrami, C. A., Nadal-Ginard,
B., et al. (2002). Chimerism of the transplanted heart.N. Engl. J. Med. 346, 5–15.
doi: 10.1056/NEJMoa012081
Quarti, A., Nardone, S., Colaneri, M., Santoro, G., and Pozzi, M. (2011).
Preliminary experience in the use of an extracellular matrix to repair
congenital heart diseases. Interact. Cardiovasc. Thorac. Surg. 13, 569–572. doi:
10.1510/icvts.2011.280016
Razzouk, A. J., and Bailey, L. L. (2014). Heart transplantation in children for end-
stage congenital heart disease. Semin. Thorac. Cardiovasc. Surg. Pediatr. Card.
Surg. Annu. 17, 69–76. doi: 10.1053/j.pcsu.2014.01.009
Reddy, S., Zhao, M., Hu, D. Q., Fajardo, G., Katznelson, E., Punn, R., et al.
(2013). Physiologic and molecular characterization of a murine model of
Frontiers in Cell and Developmental Biology | www.frontiersin.org 15 June 2015 | Volume 3 | Article 39
Avolio et al. Tissue engineering for CHD correction
right ventricular volume overload. Am. J. Physiol. Heart Circ. Physiol. 304,
H1314–H1327. doi: 10.1152/ajpheart.00776.2012
Rieder, E., Kasimir, M. T., Silberhumer, G., Seebacher, G., Wolner, E., Simon,
P., et al. (2004). Decellularization protocols of porcine heart valves differ
importantly in efficiency of cell removal and susceptibility of the matrix to
recellularization with human vascular cells. J. Thorac. Cardiovasc. Surg. 127,
399–405. doi: 10.1016/j.jtcvs.2003.06.017
Roh, J. D., Nelson, G. N., Udelsman, B. V., Brennan, M. P., Lockhart, B., Fong, P.
M., et al. (2007). Centrifugal seeding increases seeding efficiency and cellular
distribution of bone marrow stromal cells in porous biodegradable scaffolds.
Tissue Eng. 13, 2743–2749. doi: 10.1089/ten.2007.0171
Roh, J. D., Sawh-Martinez, R., Brennan, M. P., Jay, S. M., Devine, L., Rao, D. A.,
et al. (2010). Tissue-engineered vascular grafts transform into mature blood
vessels via an inflammation-mediated process of vascular remodeling. Proc.
Natl. Acad. Sci. U.S.A. 107, 4669–4674. doi: 10.1073/pnas.0911465107
Rose, R. A., Jiang, H., Wang, X., Helke, S., Tsoporis, J. N., Gong, N., et al.
(2008). Bone marrow-derived mesenchymal stromal cells express cardiac-
specific markers, retain the stromal phenotype, and do not become functional
cardiomyocytes in vitro. Stem Cells 26, 2884–2892. doi: 10.1634/stemcells.2008-
0329
Ruel, M., Kulik, A., Lam, B. K., Rubens, F. D., Hendry, P. J., Masters, R. G., et al.
(2005). Long-term outcomes of valve replacement with modern prostheses in
young adults. Eur. J. Cardiothorac. Surg. 27, 425–433. discussion: 433. doi:
10.1016/j.ejcts.2004.12.002
Rupp, S., Bauer, J., Tonn, T., Schachinger, V., Dimmeler, S., Zeiher, A. M.,
et al. (2009). Intracoronary administration of autologous bone marrow-derived
progenitor cells in a critically ill two-yr-old child with dilated cardiomyopathy.
Pediatr. Transplant. 13, 620–623. doi: 10.1111/j.1399-3046.2008.01024.x
Rupp, S., Bauer, J., von Gerlach, S., Fichtlscherer, S., Zeiher, A. M., Dimmeler, S.,
et al. (2012a). Pressure overload leads to an increase of cardiac resident stem
cells. Basic Res. Cardiol. 107, 252. doi: 10.1007/s00395-012-0252-x
Rupp, S., Jux, C., Bonig, H., Bauer, J., Tonn, T., Seifried, E., et al. (2012b).
Intracoronary bone marrow cell application for terminal heart failure in
children. Cardiol. Young 22, 558–563. doi: 10.1017/S1047951112000066
Rupp, S., Zeiher, A. M., Dimmeler, S., Tonn, T., Bauer, J., Jux, C., et al. (2010).
A regenerative strategy for heart failure in hypoplastic left heart syndrome:
intracoronary administration of autologous bone marrow-derived progenitor
cells. J. Heart Lung Transplant. 29, 574–577. doi: 10.1016/j.healun.2009.10.006
Ruzmetov, M., Shah, J. J., Geiss, D. M., and Fortuna, R. S. (2012). Decellularized
versus standard cryopreserved valve allografts for right ventricular outflow tract
reconstruction: a single-institution comparison. J. Thorac. Cardiovasc. Surg.
143, 543–549. doi: 10.1016/j.jtcvs.2011.12.032
Said, S. M., and Burkhart, H. M. (2014). When repair is not feasible:
prosthesis selection in children and adults with congenital heart disease.
Semin. Thorac. Cardiovasc. Surg. Pediatr. Card. Surg. Annu. 17, 22–29. doi:
10.1053/j.pcsu.2014.01.002
Sanganalmath, S. K., and Bolli, R. (2013). Cell therapy for heart failure:
a comprehensive overview of experimental and clinical studies,
current challenges, and future directions. Circ. Res. 113, 810–834. doi:
10.1161/CIRCRESAHA.113.300219
Schmidt, D., Stock, U. A., and Hoerstrup, S. P. (2007). Tissue engineering of heart
valves using decellularized xenogeneic or polymeric starter matrices. Philos.
Trans. R. Soc. Lond. B Biol. Sci. 362, 1505–1512. doi: 10.1098/rstb.2007.2131
Scholl, F. G., Boucek, M. M., Chan, K. C., Valdes-Cruz, L., and Perryman, R.
(2010). Preliminary experience with cardiac reconstruction using decellularized
porcine extracellular matrix scaffold: human applications in congenital
heart disease. World J. Pediatr. Congenit. Heart Surg. 1, 132–136. doi:
10.1177/2150135110362092
Selem, S. M., Kaushal, S., and Hare, J. M. (2013). Stem cell therapy for pediatric
dilated cardiomyopathy. Curr. Cardiol. Rep. 15:369. doi: 10.1007/s11886-013-
0369-z
Shetty, R., Pibarot, P., Audet, A., Janvier, R., Dagenais, F., Perron, J., et al. (2009).
Lipid-mediated inflammation and degeneration of bioprosthetic heart valves.
Eur. J. Clin. Invest. 39, 471–480. doi: 10.1111/j.1365-2362.2009.02132.x
Shinoka, T., Breuer, C. K., Tanel, R. E., Zund, G., and Miura, T., Ma, P. X., et al.
(1995). Tissue engineering heart valves: valve leaflet replacement study in a
lamb model. Ann. Thorac. Surg. 60(6 Suppl.), S513–S516. doi: 10.1016/0003-
4975(95)00733-4
Shin’oka, T., Imai, Y., and Ikada, Y. (2001). Transplantation of a tissue-
engineered pulmonary artery. N. Engl. J. Med. 344, 532–533. doi:
10.1056/NEJM200102153440717
Shin’oka, T., Matsumura, G., Hibino, N., Naito, Y., Watanabe, M., Konuma, T.,
et al. (2005). Midterm clinical result of tissue-engineered vascular autografts
seeded with autologous bone marrow cells. J. Thorac. Cardiovasc. Surg. 129,
1330–1338. doi: 10.1016/j.jtcvs.2004.12.047
Simari, R. D., Pepine, C. J., Traverse, J. H., Henry, T. D., Bolli, R., Spoon, D. B., et al.
(2014). Bonemarrowmononuclear cell therapy for acutemyocardial infarction:
a perspective from the cardiovascular cell therapy research network. Circ. Res.
114, 1564–1568. doi: 10.1161/CIRCRESAHA.114.303720
Simon, P., Aschauer, C., Moidl, R., Marx, M., Keznickl, F. P., Eigenbauer, E.,
et al. (2001). Growth of the pulmonary autograft after the Ross operation
in childhood. Eur. J. Cardiothorac. Surg. 19, 118–121. doi: 10.1016/S1010-
7940(00)00638-2
Simpson, D. L., Mishra, R., Sharma, S., Goh, S. K., Deshmukh, S., and
Kaushal, S. (2012). A strong regenerative ability of cardiac stem cells
derived from neonatal hearts. Circulation 126(11 Suppl. 1), S46–S53. doi:
10.1161/CIRCULATIONAHA.111.084699
Smit, F. E., and Dohmen, P. M. (2015). Cardiovascular tissue engineering: where
we come from and where are we now?Med. Sci. Monit. Basic Res. 21, 1–3. doi:
10.12659/MSMBR.893546
Strange, G., Brizard, C., Karl, T. R., and Neethling, L. (2015). An evaluation of
Admedus’ tissue engineering process-treated (ADAPT) bovine pericardium
patch (CardioCel) for the repair of cardiac and vascular defects. Expert Rev.
Med. Devices 12, 135–141. doi: 10.1586/17434440.2015.985651
Sun, R., Liu, M., Lu, L., Zheng, Y., and Zhang, P. (2015). Congenital heart
disease: causes, diagnosis, symptoms, and treatments. Cell Biochem. Biophys.
doi: 10.1007/s12013-015-0551-6. [Epub ahead of print].
Sutherland, F. W., Perry, T. E., Yu, Y., Sherwood, M. C., Rabkin, E., Masuda,
Y., et al. (2005). From stem cells to viable autologous semilunar heart valve.
Circulation 111, 2783–2791. doi: 10.1161/CIRCULATIONAHA.104.498378
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., et al.
(2007). Induction of pluripotent stem cells from adult human fibroblasts by
defined factors. Cell 131, 861–872. doi: 10.1016/j.cell.2007.11.019
Tarui, S., Sano, S., and Oh, H. (2014). Stem cell therapies in patients with
single ventricle physiology. Methodist Debakey Cardiovasc. J. 10, 77–81. doi:
10.14797/mdcj-10-2-77
Tateishi, K., Ashihara, E., Honsho, S., Takehara, N., Nomura, T., Takahashi,
T., et al. (2007). Human cardiac stem cells exhibit mesenchymal features
and are maintained through Akt/GSK-3beta signaling. Biochem. Biophys. Res.
Commun. 352, 635–641. doi: 10.1016/j.bbrc.2006.11.096
Tendera, M., Wojakowski, W., Ruzyllo, W., Chojnowska, L., Kepka, C., Tracz,
W., et al. (2009). Intracoronary infusion of bone marrow-derived selected
CD34+CXCR4+ cells and non-selectedmononuclear cells in patients with acute
STEMI and reduced left ventricular ejection fraction: results of randomized,
multicentre Myocardial Regeneration by Intracoronary Infusion of Selected
Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur.
Heart J. 30, 1313–1321. doi: 10.1093/eurheartj/ehp073
Tennant, P. W., Pearce, M. S., Bythell, M., and Rankin, J. (2010). 20-year survival
of children born with congenital anomalies: a population-based study. Lancet
375, 649–656. doi: 10.1016/S0140-6736(09)61922-X
Torella, D., Ellison, G. M., Karakikes, I., and Nadal-Ginard, B. (2007). Resident
cardiac stem cells. Cell. Mol. Life Sci. 64, 661–673. doi: 10.1007/s00018-007-
6519-y
Torella, D., Ellison, G. M., Mendez-Ferrer, S., Ibanez, B., and Nadal-Ginard, B.
(2006). Resident human cardiac stem cells: role in cardiac cellular homeostasis
and potential for myocardial regeneration. Nat. Clin. Pract. Cardiovasc. Med.
3(Suppl. 1), S8–S13. doi: 10.1038/ncpcardio0409
Torigoe, I., Sotome, S., Tsuchiya, A., Yoshii, T., Takahashi, M., Kawabata,
S., et al. (2007). Novel cell seeding system into a porous scaffold using
a modified low-pressure method to enhance cell seeding efficiency and
bone formation. Cell Transplant. 16, 729–739. doi: 10.3727/000000007783
465109
Tudorache, I., Cebotari, S., Sturz, G., Kirsch, L., Hurschler, C., Hilfiker, A., et al.
(2007). Tissue engineering of heart valves: biomechanical and morphological
properties of decellularized heart valves. J. Heart Valve Dis. 16, 567–573.
discussion: 574.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 16 June 2015 | Volume 3 | Article 39
Avolio et al. Tissue engineering for CHD correction
Tweddell, J. S., Pelech, A. N., Frommelt, P. C., Mussatto, K. A., Wyman,
J. D., Fedderly, R. T., et al. (2000). Factors affecting longevity of
homograft valves used in right ventricular outflow tract reconstruction for
congenital heart disease. Circulation 102(19 Suppl. 3), III130–III135. doi:
10.1161/01.cir.102.suppl_3.iii-130
Uccelli, A., Moretta, L., and Pistoia, V. (2008). Mesenchymal stem cells in health
and disease. Nat. Rev. Immunol. 8, 726–736. doi: 10.1038/nri2395
Uemura, R., Xu, M., Ahmad, N., and Ashraf, M. (2006). Bone marrow stem
cells prevent left ventricular remodeling of ischemic heart through paracrine
signaling. Circ. Res. 98, 1414–1421. doi: 10.1161/01.RES.0000225952.61196.39
Vacanti, C. A., Paige, K. T., Kim, W. S., Sakata, J., Upton, J., and Vacanti,
J. P. (1994). Experimental tracheal replacement using tissue-engineered
cartilage. J. Pediatr. Surg. 29, 201–204. discussion: 204–205. doi: 10.1016/0022-
3468(94)90318-2
Vincentelli, A., Wautot, F., Juthier, F., Fouquet, O., Corseaux, D., Marechaux, S.,
et al. (2007). In vivo autologous recellularization of a tissue-engineered heart
valve: are bone marrow mesenchymal stem cells the best candidates? J. Thorac.
Cardiovasc. Surg. 134, 424–432. doi: 10.1016/j.jtcvs.2007.05.005
Wald, R. M., Marie Valente, A., and Marelli, A. (2014). Heart failure in adult
congenital heart disease: emerging concepts with a focus on tetralogy of Fallot.
Trends Cardiovasc. Med. 25, 422–432. doi: 10.1016/j.tcm.2014.11.011
Williams, A. R., Hatzistergos, K. E., Addicott, B., McCall, F., and Carvalho, D.,
Suncion, V., et al. (2013). Enhanced effect of combining human cardiac stem
cells and bone marrow mesenchymal stem cells to reduce infarct size and to
restore cardiac function after myocardial infarction. Circulation 127, 213–223.
doi: 10.1161/CIRCULATIONAHA.112.131110
Witt, R. G., Raff, G., Van Gundy, J., Rodgers-Ohlau, M., and Si, M. S. (2013).
Short-term experience of porcine small intestinal submucosa patches in
paediatric cardiovascular surgery. Eur. J. Cardiothorac. Surg. 44, 72–76. doi:
10.1093/ejcts/ezs638
Wohrle, J., Merkle, N., Mailander, V., Nusser, T., Schauwecker, P., von Scheidt, F.,
et al. (2010). Results of intracoronary stem cell therapy after acute myocardial
infarction. Am. J. Cardiol. 105, 804–812. doi: 10.1016/j.amjcard.2009.10.060
Woodward, C. S. (2011). Keeping children with congenital heart disease healthy.
J. Pediatr. Health Care 25, 373–378. doi: 10.1016/j.pedhc.2011.03.007
Wu, K. H., Mo, X. M., Zhou, B., Lu, S. H., Yang, S. G., Liu, Y. L., et al. (2009).
Cardiac potential of stem cells from whole human umbilical cord tissue. J. Cell.
Biochem. 107, 926–932. doi: 10.1002/jcb.22193
Xin, Z., Meng, W., Ya-Ping, H., and Wei, Z. (2008). Different biological properties
of circulating and bonemarrow endothelial progenitor cells in acutemyocardial
infarction rats. Thorac. Cardiovasc. Surg. 56, 441–448. doi: 10.1055/s-2008-
1038879
Yap, K. H., Murphy, R., Devbhandari, M., and Venkateswaran, R. (2013). Aortic
valve replacement: is porcine or bovine valve better? Interact. Cardiovasc.
Thorac. Surg. 16, 361–373. doi: 10.1093/icvts/ivs447
Yoder, M. C. (2015). Differentiation of pluripotent stem cells into endothelial cells.
Curr. Opin. Hematol. 22, 252–257. doi: 10.1097/MOH.0000000000000140
Yoon, C. H., Koyanagi, M., Iekushi, K., Seeger, F., Urbich, C., Zeiher, A.
M., et al. (2010). Mechanism of improved cardiac function after bone
marrow mononuclear cell therapy: role of cardiovascular lineage commitment.
Circulation 121, 2001–2011. doi: 10.1161/CIRCULATIONAHA.109.909291
Yoon, Y. S., Wecker, A., Heyd, L., Park, J. S., Tkebuchava, T., Kusano, K., et al.
(2005). Clonally expanded novel multipotent stem cells from human bone
marrow regenerate myocardium after myocardial infarction. J. Clin. Invest. 115,
326–338. doi: 10.1172/JCI200522326
Young, P. P., Vaughan, D. E., and Hatzopoulos, A. K. (2007). Biologic properties
of endothelial progenitor cells and their potential for cell therapy. Prog.
Cardiovasc. Dis. 49, 421–429. doi: 10.1016/j.pcad.2007.02.004
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.
L., Tian, S., et al. (2007). Induced pluripotent stem cell lines derived
from human somatic cells. Science 318, 1917–1920. doi: 10.1126/science.
1151526
Yuan, S. M., and Jing, H. (2009). Palliative procedures for congenital heart
defects. Arch. Cardiovasc. Dis. 102, 549–557. doi: 10.1016/j.acvd.2009.
04.011
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2015 Avolio, Caputo and Madeddu. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 17 June 2015 | Volume 3 | Article 39
